Molgramostim Improves Exercise Capacity, Distance Walked, and Duration of Exercise in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial

Home / Molgramostim Improves Exercise Capacity, Distance Walked, and Duration of Exercise in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial

Learn more

We use cookies to give you the best online experience. By accepting, you agree to the use of cookies in accordance with our cookie policy.

I Accept I Decline